# Where ScienceTakes Shape

**We are a leading early-stage venture capital firm dedicated to investing in the most innovative life science companies in Europe.**

By investing early and partnering with visionary CEOs, we strive to have a transformative impact on healthcare.

We leverage our deep sector expertise, entrepreneurial experience, and strong network across academia, industry and clinical research institutions to help build exceptional companies.

[This is Thuja](https://www.thujacapital.com/this-is-thuja/)

## Today’s scientific breakthroughs, tomorrow’s impact.

[Portfolio](http://www.thujacapital.com/portfolio/)

## Latest stories

![](https://www.thujacapital.com/)

May 21, 2025

## Gradient Denervation Technologies announces FDA breakthrough designation for Pulmonary Artery Denervation System

![](https://www.thujacapital.com/)

May 20, 2025

## A new chapter begins. AstraZeneca has completed their acquisition of EsoBiotec

![](https://www.thujacapital.com/wp-content/uploads/2025/03/Michel.png)

May 8, 2025

## Meet Michel Briejer, Managing Partner at Thuja Capital

[All stories](https://www.thujacapital.com/stories/)

## Sign up

#### Subscribe to our newsletter.

Subscribe

Leave this field empty if you're human:

## Empowering breakthrough innovations that transform healthcare